LDLR and hyperlipidemia: In an early study, intravenous or parenteral HPβCD reduced serum cholesterol levels and aortic atherosclerotic lesions in rabbits with hyperlipidemia of genetic origin [205] and improved intracellular cholesterol distribution in Kupffer cells in LDLR (low-density lipoprotein receptor) knockout mice on a high-fat high-cholesterol diet [206].